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Key summary points
Aim To test whether renal biochemical markers were associated with physical performance and frailty in older people with 
advanced chronic kidney disease.
Findings Biochemical markers associated with chronic kidney disease did not consistently associate with baseline physical 
performance or the rate of change of physical performance measures.
Message Targeting improvements in renal biochemistry may not be a fruitful way to improve physical function and frailty 
in older people with advanced chronic kidney disease.
Abstract
Purpose Impaired physical performance and frailty are common in older people with advanced chronic kidney disease but 
it is unclear which metabolic derangements contribute to these impairments. We, therefore, examined associations between 
renal biochemical markers and both physical performance and frailty in older people with advanced chronic kidney disease.
Methods Secondary analysis of data from the BiCARB trial, which enrolled non-dialysing patients aged 60 and over, with 
chronic kidney disease stage 4/5, with serum bicarbonate < 22 mmol/L. Participants undertook the Short Physical Perfor-
mance Battery, maximum grip strength and six-minute walk test at baseline, 3, 6, 12 and 24 months. Renal biochemistry 
(serum creatinine, cystatin C, phosphate, and bicarbonate), haemoglobin, 25-hydroxyvitamin D and NT-pro-B-type natriu-
retic peptide were measured at baseline. Associations between baseline renal biochemistry and physical performance, and 
between baseline biochemistry and the monthly rate of change in physical performance were assessed.
Results We analysed data from 300 participants (mean age 74 years; 86 [29%] women). 148 (49%) were pre-frail, 86 (29%) 
were frail. In multivariable cross-sectional baseline analyses, only age and BMI were significantly associated with baseline 
short physical performance battery; age, sex, body mass index, NT-pro-BNP and 25-hydroxyvitamin D were significantly 
associated with baseline six-minute walk distance. No significant associations were found between biochemical markers 
and change in physical performance over time, except between baseline 25-hydroxyvitamin D concentration and change in 
six-minute walk distance.
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Conclusions Biochemical markers associated with chronic kidney disease did not consistently associate with baseline physi-
cal performance or the rate of change of physical performance measures.
Trial Registration: ISRCTN09486651
Keywords Chronic kidney disease · Biomarkers · Physical performance · Frailty
Introduction
Frailty is a state of impaired homeostasis and reduced 
physiological reserve such that a minor stressor event 
causes a disproportionately large decline in health sta-
tus [1]. Frailty is independently associated with a range 
of adverse outcomes that include premature mortality, 
increased risk of hospital admission, longer length of hos-
pital stay and future disability [2–4]. Impaired physical 
performance is a key component of the physical frailty 
syndrome, and measures of physical performance (low 
handgrip strength and low walk speed) feature in the frailty 
phenotype described by Fried et al. [5] along with weight 
loss, exhaustion and low physical activity levels. Frailty is 
common in patients with advanced chronic kidney disease 
(CKD), with a prevalence of up to 73% in those on mainte-
nance haemodialysis [6, 7]; this compares to a prevalence 
of approximately 10% in the general population aged 65 
and over [8]. Frailty is an independent risk factor for a 
range of adverse events in all stages of CKD [9].
Before interventions to prevent or improve frailty 
and physical performance in patients with CKD can be 
designed, a better understanding of the factors associ-
ated with frailty and impaired physical performance in 
this population is required. Several pathophysiological 
processes that are present in CKD could plausibly affect 
skeletal muscle function, thus leading to impaired physical 
performance and hence physical frailty. These include but 
are not limited to: reduction of food intake (particularly 
protein), persistent inflammation, oxidative stress, meta-
bolic acidosis, anaemia, impaired vitamin D metabolism, 
vascular dysfunction, uraemia, and hyperphosphataemia 
[10–12]. These factors, together with the high prevalence 
of multimorbid disease that accompanies CKD [13], may 
all play a part in driving the high prevalence of frailty seen 
in patients with CKD.
The majority of studies examining the association 
between CKD and physical performance or frailty have 
been conducted with patients undergoing dialysis [9, 14]. 
More information is, therefore, needed on how common 
frailty is in patients with advanced CKD who are not on 
dialysis—particularly older patients who are at highest risk 
of frailty. In addition, many studies to date have been cross 
sectional in nature, limiting the ability to infer causal rela-
tionships. This analysis, therefore, first aimed to describe 
the prevalence of frailty in a group of older people with 
advanced CKD not on dialysis; second to explore associa-
tions between baseline measures of physical performance 
and frailty and measures of renal pathophysiology, and 
third to describe associations between baseline measures 
of renal pathophysiology and changes in physical per-
formance during follow-up. We hypothesised that frailty 
would be common in older patients with advanced CKD 
not undergoing dialysis, that biomarkers of CKD patho-
physiology would be significantly correlated with frailty 
and impaired physical performance at baseline and would 




We analysed cross-sectional and longitudinal data collected 
as part of the BiCARB randomised controlled trial [15, 16], 
which evaluated the clinical and cost-effectiveness of oral 
sodium bicarbonate therapy for older patients with advanced 
CKD and mild metabolic acidosis. The trial was funded 
by the UK National Institute for Health Research (NIHR) 
Health Technology Assessment Board (award 10/71/01) 
and was co-sponsored by the University of Dundee and 
NHS Tayside (Tayside Academic Health Sciences Col-
laboration). Ethical approval was granted by the East of 
Scotland NHS Research Ethics Committee (approval 12/
ES/0023) and the trial was approved by the UK Medicines 
and Healthcare Regulatory Authority (EudraCT number 
2011–005,271-16; Clinical Trial Authorisation number 
41692/0001/001–0001). The trial was registered at www. 
isrctn. com (ISRCTN09486651).
Participants
The BiCARB trial enrolled 300 participants from nephrology 
and geriatric medicine clinics in 27 hospitals across the UK. 
Inclusion criteria were CKD stage 4 or 5 (eGFR < 30 ml/
min/1.73m2 by MDRD4 equation [17]), not undergoing 
dialysis, aged ≥ 60 years, with a serum bicarbonate level at 
screening of < 22 mmol/L. A full list of exclusion criteria 
has been published previously [15]. In the BiCARB trial, 
administration of oral bicarbonate had no effect on meas-
ures of physical performance or other outcomes, and all 
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participants are, therefore, included in the analyses presented 
here. Information on baseline cardiovascular comorbidities 
but not other conditions was collected.
Outcome measures
Participants performed the Short Physical Performance 
Battery (SPPB) [18], a test of lower limb function that has 
been shown to predict a range of adverse outcomes includ-
ing future disability, need for care and death [19]. The test 
consisted of three components—a balance test, a gait speed 
test, and a chair stand test. Each section was scored out of 
4 points with a maximum of 12 points denoting the high-
est level of performance. Participants performed the six-
minute walk distance (6MWD) as a submaximal test of 
cardiorespiratory function. Participants walked as far as 
possible in 6 min over a 25 m course [20] and standardised 
words of encouragement were delivered to the participant 
every 2 min. Maximal grip strength was measured using 
a Takei handgrip dynamometer. The maximum value of 
three attempts in the dominant hand was used [21]. Physi-
cal performance data were collected at baseline, 3, 6, 12 and 
24 month visits and all available data were used in these 
analyses. A frailty score was derived using prespecified cri-
teria based on the five domains outlined by Fried et al. [5]. 
A description of how the score was derived is given in the 
Supplementary Material. Age, sex and BMI were used as 
covariates.
Baseline markers of renal biochemistry
Baseline markers of renal function (serum cystatin C, cre-
atinine, and bicarbonate), markers associated with bone 
metabolism [serum phosphate and 25-hydroxyvitamin D 
(25OHD)], blood haemoglobin and serum albumin were 
measured, along with plasma NT-pro-terminal B-type 
natriuretic peptide (NT-pro-BNP) as a marker of cardiovas-
cular dysfunction. Cystatin C was measured at a central lab-
oratory using a turbidimetric immunoassay (Abbott ARCHI-
TECT analyser, Maidenhead, UK) as previously described 
[16]. NT-pro-BNP was measured at a central laboratory 
using an enzyme-linked immunosorbent assay (Meso Scale 
Discovery, Rockville, MD, USA). 25OHD was analysed by 
a central laboratory using a Chemiflex Chemiluminescence 
Microparticle Immunoassay (Abbott Diagnostics, Lake For-
est, IL, USA). All other blood biomarkers (creatinine, bicar-
bonate, phosphate, haemoglobin and albumin) were analysed 
by local hospital services as part of routine clinical care; all 
hospital laboratories participated in the UK NEQAS quality 
assurance scheme.
Statistical analyses
Analyses were performed using SPSS v25 (IBM Corp, 
Armonk, NY) and a two-sided p value of < 0.05 was taken 
to be significant for all tests. We did not adjust analyses 
for multiple statistical testing. Data were summarised using 
means or medians and measures of variability were reported 
as standard deviation, interquartile range or 95% CI. Bivari-
ate correlations between measures of physical performance 
and baseline biomarkers were derived using Pearson’s cor-
relation coefficient or Spearman’s rho for skewed variables. 
Multivariable linear regression models were run using 
forced entry of all variables with the exception of serum 
phosphate, which could not be included because of high 
levels of missing data. Baseline measures across frailty cat-
egories were compared using independent samples t tests for 
normally distributed variables, or Mann–Whitney U tests 
for non-normally distributed variables. Categorical com-
parisons were conducted using Pearson’s chi-squared test 
(or Fisher’s exact test where any cell contained 5 or fewer 
cases). For each variable, non-frail was used as the referent 
category. The relationship between baseline cardiovascu-
lar comorbidities and physical performance measures was 
also described through univariate analyses. Student’s t tests 
were used for continuous baseline variables; general linear 
models with adjustment for baseline physical performance 
measures were used for change in physical performance over 
time, and Chi-squared and Fisher’s exact tests were used 
to analyse associations between baseline comorbidities and 
frailty categories.
The rate of change in physical performance was calcu-
lated for each individual using the slope of the regression 
line for time vs physical performance measures. For each 
individual, all available data points were included (i.e. par-
ticipants were included if baseline and at least one follow-up 
measurement was available), and a slope value depicting rate 
of change per month of follow-up was generated. Rate of 
change was correlated with baseline physical performance 
for all measures; all correlations between rate of change and 
baseline biomarkers were therefore adjusted for the base-
line value of the physical performance measure under test. 
Finally, multivariable linear regression was used to examine 
the relationship between baseline variables (including base-
line physical performance) and rate of change in physical 
performance, again using forced entry of variables. Comor-
bidities were not included in multivariable analyses as they 
were likely to lie on the causal pathway between biochemical 
measures and physical performance in most cases and their 
inclusion would therefore prevent any effect of biochemical 
variables on physical performance from being apparent in 
the analyses. The sample size for this analysis (n = 300) was 
constrained by the numbers recruited to the BiCARB trial.
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Table 1  Baseline details 
(n = 300)
All data are mean (SD) unless otherwise specified
BMI body mass index, eGFR estimated glomerular filtration rate, 25OHD 25-hydroxyvitamin D, NT-pro-
BNP N-terminal pro B-type natriuretic peptide
*Defined as previous myocardial infarction or coronary revascularisation
Age (years) (SD) 74.0 (7.1)
Male sex (%) 214 (71)
eGFR category (%) Stage 4 218 (72.7)
Stage 5 82 (27.3)
Ethnicity (%) White 287 (95.7)
Far east asian 1 (0.3)
Black african 1 (0.3)
South asian 6 (2.0)
Hispanic 1 (0.3)
Other 4 (1.3)
Living status (%) Living alone 91 (30.6)
Not living alone 206 (69.4)
Hypertension (%) 264 (88.0)
Diabetes mellitus (%) 101 (33.7)
Ischaemic heart disease* (%) 57 (19.0)
Stroke (%) 28 (9.3)
Peripheral vascular disease (%) 24 (8.0)
Chronic heart failure (%) 24 (8.0)
Atrial fibrillation (%) 41 (13.7)
Body mass index (kg/m2) (SD) 28.6 (4.6)
Short physical performance battery score (SD) 8.1 (2.3)
Six-minute walk distance (m) (SD) 311 (134)
Maximum grip strength (kg) (SD) Men 27.3 (8.2)
Women 15.6 (4.6)
Cystatin C (mg/l) (SD) 3.1 (0.7)
Creatinine (μmol/l) (SD) 298 (102)
Bicarbonate (mmol/l) (SD) 21.3 (3.1)
eGFR (by MDRD4 equation, ml/min/1.73m2) (SD) 19.9 (6.8)
25-hydroxyvitamin D (nmol/l) (SD) 45 (27)
Median NT-pro-BNP (pg/ml) (IQR) 6413 (1647–10,295)
Albumin (g/l) (SD) 40 (5)
Haemoglobin (g/dl) (SD) 11.6 (1.6)
Phosphate (mmol/l) (SD) 1.3 (0.3)
Frailty score components
Low grip strength (%) 156/300 (52.0)
Low gait speed (%) 159/296 (53.7)
Exhaustion (%) 151/287 (52.6)
BMI < 18.5 kg/m2 (%) 1/296 (0.3)
Low activity (%) 64/285 (22.5)
Frailty score (%) 0 Non-frail 42 (15.2)
1 Pre-frail 82 (29.7)
2 66 (23.9)
3 Frail 59 (21.4)
4 27 (9.8)
5 0 (0)
Score not calculable 24 (8.0)
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Results
Baseline details and frailty prevalence
Three hundred people were included in the analysis; baseline 
details are shown in Table 1. All participants were resident 
in their own homes; no participant was resident in a care 
home. Forty-two (14%) were non-frail, 148 (49%) were pre-
frail, 86 (29%) were frail, and 24 (8%) had incomplete data 
that meant that a frailty score could not be calculated; these 
participants were still included in the frailty analyses as a 
separate group. Supplementary Table 2 shows how many 
individuals contributed physical performance data at each 
follow-up visit.
Baseline associations with frailty
Table 2 shows the association between baseline biomarkers, 
adverse outcomes and different categories of frailty. Those 
living with frailty were older, with lower BMI, albumin, 
haemoglobin and 25OHD, and showed higher NT-pro-BNP 
concentrations than those who were non-frail, with a gradi-
ent between non-frail, pre-frail and frail evident for most of 
these variables. Biomarker measurements for participants 
where frailty could not be evaluated were similar to those 
with frailty. Trial dropout rates and death rates showed the 
expected relationship with frailty, being lowest in non-
frail participants and highest in those with frailty or those 
people unable to complete frailty scoring. Falls rates were 
higher in those with frailty or pre-frailty than those who 
were non-frail. In contrast, adverse event rates were similar 
across all frailty categories. Baseline associations between 
cardiovascular comorbidities and frailty category are shown 
in Supplementary Table 3; peripheral vascular disease was 
the only comorbidity significantly associated with frailty in 
this analysis.
Baseline correlations of physical performance
Table 3 shows the results of univariate associations with 
physical performance. Age, sex, BMI, NT-pro-BNP, albu-
min, and haemoglobin showed significant associations 
with SPPB score. For the 6MWD, age, cystatin C, BMI, 
NT-pro-BNP, 25-hydroxyvitamin D, albumin, and hae-
moglobin showed significant associations. For men, hand 
grip strength was associated with age, cystatin C, and BNP; 
different associations were seen for women with only age 
and 25-hydroxyvitamin D showing significant associations 
with grip strength. Univariate associations between baseline 
comorbidities and physical performance measures are given 
in Supplementary Table 4; diabetes mellitus, heart failure 
and atrial fibrillation were most consistently associated 
Table 2  Association of baseline variables and adverse outcomes with baseline frailty status
*p < 0.05 **p < 0.01 vs non-frail










Age (years) (SD) 70.7 (5.0) 73.3 (7.1)** 76.2 (7.3)** 75.6 (7.2)**
Cystatin C (mg/l) (SD) 2.9 (0.8) 3.1 (0.7)* 3.2 (0.7)** 3.2 (0.8)
Creatinine (μmol/l) (SD) 279 (93) 299 (93) 298 (115) 321 (121)
Bicarbonate (mmol/l) (SD) 21.0 (2.1) 21.2 (3.2) 21.4 (3.2) 21.1 (3.1)
BMI (kg/m2) (SD) 28.9 (3.8) 28.5 (4.0) 29.1 (5.8) 26.9 (3.3)*
eGFR by MDRD4 (ml/min/1.73m2) (SD) 20.9 (7.0) 20.0 (6.8) 19.7 (6.9) 18.2 (6.5)
25OHD (nmol/l) (SD) 55 (35) 45 (27) 42 (24)* 33 (19)*
Median NT-pro-BNP (pg/ml) (IQR) 4258 (407–
6824)




Albumin (g/l) (SD) 41 (5) 40 (4) 39 (5)* 38 (5)*
Haemoglobin (g/dl) (SD) 12.1 (1.5) 11.7 (1.7) 11.4 (1.4)* 11.2 (1.4)*
Phosphate (mmol/l) (SD) 1.3 (0.3) 1.3 (0.4) 1.2 (0.3) 1.4 (0.2)
Adverse outcomes
Median number of adverse events (IQR) 2 (1 to 4) 2 (1 to 4) 3 (2 to 4) 2 (1 to 3)
Falls rate (per 1000 days) Mean (SD) 0.27 (0.75) 1.63 (3.58) 1.46 (3.43) 1.58 (2.60)
Median (IQR) 0 (0 to 0) 0 (0 to 2.22)** 0 (0 to 1.45)** 0 (0 to 2.87)*
Dropout by 12 months (%) 6 (14) 32 (22) 27 (31)* 9 (38)*
Death by 12 months (%) 0 (0) 7 (5) 6 (7) 2 (8)
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with worse physical performance. In multivariable analysis, 
only age and BMI were significantly associated with base-
line SPPB; age, sex, BMI, NT-pro-BNP and 25OHD were 
all significantly associated with baseline 6MWD, but grip 
strength was significantly associated only with age (for men) 
and cystatin C (for women). Full details of the multivariable 
models are given in Supplementary Table 5.
Table 3  Baseline associations between biomarkers and physical performance measures
All Pearson’s correlations except for *Spearman’s rho
SPPB Short Physical Performance Battery, 6WMD Six-minute walk distance, BMI body mass index, eGFR estimated glomerular filtration rate, 
25OHD 25-hydroxyvitamin D, NT-pro-BNP N-terminal pro B-type natriuretic peptide
Variable SPPB 6MWT Grip (men) Grip (women)
r p r p r p r p
Age (years) − 0.28  < 0.001 − 0.33  < 0.001 − 0.30  < 0.001 − 0.28 0.008
Cystatin C (mg/l) − 0.10 0.13 − 0.19 0.002 − 0.17 0.02 − 0.22 0.07
Creatinine (μmol/l) 0.02 0.72 0.04 0.51 − 0.06 0.41 − 0.08 0.45
Bicarbonate (mmol/l) − 0.11 0.06 0.01 0.86 0.02 0.73 − 0.05 0.67
BMI(kg/m2) 0.12 0.05 − 0.18 0.002 0.05 0.46 0.07 0.51
eGFR (ml/min/1.73m2) 0.01 0.83 0.04 0.50 0.06 0.42 0.06 0.61
25OHD (nmol/l) 0.17 0.02 0.25  < 0.001 0.10 0.20 0.26 0.05
NT-pro-BNP (pg/ml)* − 0.27  < 0.001 − 0.32  < 0.001 − 0.31  < 0.001 − 0.12 0.35
Albumin (g/l) 0.14 0.02 0.20  < 0.001 0.12 0.10 0.10 0.35
Haemoglobin (g/dl) 0.15 0.014 0.22  < 0.001 0.12 0.08 0.10 0.38
Phosphate (mmol/l) − 0.07 0.28 − 0.01 0.89 − 0.07 0.35 0.02 0.86
Mean (SD) p Mean (m) (SD) p
Sex Men 8.3 (2.2) 0.01 328 (129) 0.001 N/A N/A N/A N/A
Women 7.5 (2.4) 270 (137) N/A N/A N/A N/A
Table 4  Univariate associations between baseline variables and rate of change in physical performance
Partial correlations, adjusting for baseline value of physical performance measure in each analysis
SPPB Short Physical Performance Battery, 6WMD Six-minute walk distance, BMI body mass index, eGFR estimated glomerular filtration rate, 
25OHD 25-hydroxyvitamin D, NT-pro-BNP N-terminal pro B-type natriuretic peptide
Variable SPPB 6MWD Grip (men and women)
r p r P r p
Age (years) − 0.11 0.17 − 0.08 0.31 − 0.11 0.18
Cystatin C (mg/l) − 0.01 0.95 − 0.02 0.85 0.00 0.98
Creatinine (μmol/l) − 0.02 0.79 − 0.05 0.54 0.00 0.98
Bicarbonate (mmol/l) − 0.05 0.53 0.09 0.28 0.05 0.52
BMI (kg/m2) − 0.04 0.61 − 0.09 0.26 0.05 0.54
eGFR by MDRD4 (ml/
min/1.73m2)
− 0.02 0.82 0.05 0.57 0.07 0.35
25OHD (nmol/l) 0.01 0.95 0.15 0.06 − 0.05 0.56
NT-pro-BNP (pg/ml) − 0.08 0.32 − 0.09 0.28 0.00 0.98
Albumin (g/l) − 0.01 0.87 0.06 0.46 − 0.11 0.16
Haemoglobin (g/dl) − 0.05 0.55 0.11 0.16 0.05 0.54
Phosphate (mmol/l) − 0.06 0.50 − 0.09 0.25 − 0.08 0.34
Mean (points per month) (SD) p Mean (m per month) (SD) P Mean (Kg per month) (SD) p
Sex Men − 0.03 (− 0.07 to 0.01) 0.21 − 3.0 (− 5.0 to − 1.0) 0.56 − 0.04 (− 0.15 to 0.07) 0.08
Women 0.02 (− 0.05 to 0.08) − 1.8 (− 5.1 to 1.5) − 0.26 (− 0.46 to − 0.06)
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Associations with change in physical performance 
over time
Mean rates of change in physical performance were -0.02 
(SD 0.25) points per month for SPPB, − 2.6 (SD 14.2) 
metres per month for 6MWD, and − 0.1 (SD 0.8) kg per 
month for grip strength. Table 4 shows associations between 
single baseline biomarkers and the rate of change (change 
per month) in physical performance measures over the fol-
low-up period. For each measure of physical performance, 
higher baseline values correlated with a faster rate of fall in 
performance (regression to the mean) and so all results are 
adjusted for baseline physical performance. No significant 
association was seen between any baseline variable and the 
rate of change of any of the physical performance measures 
in univariate analyses. Univariate associations between base-
line comorbidities and physical performance measures are 
given in Supplementary Table 6; no consistent association 
between baseline comorbidity and rate of change of physical 
performance measures was seen. Multivariable analyses are 
shown in Supplementary Table 7; only the baseline physi-
cal performance was associated with the rate of change of 
physical performance, together with baseline 25OHD con-
centration which was associated with the rate of change in 
6MWD only.
Discussion
In this analysis, we found that frailty prevalence was higher 
in this group of participants with advanced CKD compared 
to the general older population. Most previous studies have 
focussed on patients on dialysis rather than on the much 
larger group of patients with advanced CKD who are not 
maintained on dialysis. The derived frailty categorisation 
was associated with adverse outcomes known to be related 
to the frailty syndrome, although total adverse events were 
similar in frequency across all frailty categories. Frailty 
was associated with greater age, lower 25OHD, albumin 
and haemoglobin concentrations and higher concentrations 
of cystatin C and NT-pro-BNP. The biomarkers studied did 
not consistently associate with either baseline measures of 
physical performance or with the rate of change in physi-
cal performance over time, and with the exception of some 
relationships with baseline six-minute walk distance (for 
25OHD and NT-pro-BNP), the biomarkers studied were 
not independently associated with physical performance. 
Our results suggest that these markers may not be the right 
targets on which to focus interventions to improve frailty and 
physical performance in older people with advanced CKD, 
and that other approaches may be needed.
Our results are consistent with previous studies that have 
found a high prevalence of frailty in people with CKD. 
Given the age of our study sample (which is older than those 
enrolled in most CKD trials), this result is not unexpected 
but illustrates that it is not just patients with CKD on dialysis 
in whom frailty is very common. Impaired physical per-
formance is a key component of the frailty syndrome, and 
participants in the trial had low 6MWD, low grip strength 
and low SPPB scores. The biochemical markers of CKD 
that we studied were not associated with differences in 
either physical performance at baseline or the trajectory of 
decline. This suggests that at least in this older population 
with advanced CKD, factors unrelated to the measured bio-
chemical derangements, but caused by CKD may be more 
important in explaining impaired physical performance. It is 
important to note that the study population had high levels 
of comorbid disease [16], including conditions that would 
also be expected to impact on physical performance such as 
arthritis, cardiovascular disease and lung disease. It is, there-
fore, possible that these conditions were more important 
drivers of impaired physical performance than CKD itself. 
Another alternative is that aspects of deranged metabolism 
seen in CKD, but not measured directly in this study, could 
still be associated with impaired physical performance. It 
is unlikely that any association was affected by participants 
taking either bicarbonate or placebo since the main BiCARB 
trial findings did not show any significant differences in any 
outcome measures, including physical performance, between 
the intervention and placebo groups [16]. A number of urae-
mic toxins (e.g. indoxyl sulphate [27]) have been postulated 
to have direct effects on neurological and skeletal muscle 
function, and levels of these unmeasured toxins may not 
have been fully reflected by the markers (e.g. estimated 
GFR) employed in this analysis.
A systematic review published in 2018 [14] found cross-
sectional associations between estimated GFR and both 
frailty and measures of physical performance including 
SPPB, 400 m walk, and self-reported disability. Equations 
using cystatin C rather than creatinine showed stronger 
associations, particularly with handgrip strength; this is 
likely to be due to the fact that low muscle mass (known 
to be associated with lower muscle strength) is associated 
with lower creatinine concentrations (and therefore a higher 
estimated GFR), leading to confounding of the relationship 
between eGFR and muscle mass. These studies examined 
older people with a range of kidney function from normal 
GFR through to kidney failure (GFR < 15 mL/min/1.73  m2). 
Although our study examined a narrower range of kidney 
function than these studies, our results were broadly com-
parable. Similarly, lower kidney function at baseline in lon-
gitudinal studies in this systematic review was associated 
with a higher risk of new disability or frailty in studies using 
cystatin C but this relationship was not always evident in 
studies using creatinine. Studies reported in this systematic 
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review did not attempt to dissect out which aspects of met-
abolic derangement seen in CKD might be related to the 
presence of impaired physical performance. Additional 
data are expected on the relationship between kidney func-
tion and physical performance from the large Screening for 
Chronic Kidney Disease among Older People across Europe 
(SCOPE) study, which has enrolled 2500 people aged 75 and 
over [29]; initial results reinforce the confounding effect of 
muscle mass on the interpretation of eGFR equations.
Our analysis has a number of strengths; we were able 
to analyse data from older people with advanced CKD and 
with multiple morbidities, collected from multiple centres in 
a single country. This group of patients are typical of those 
seen in clinical practice but are less commonly enrolled 
in either trials or observational studies of kidney disease. 
Furthermore, we were able to analyse data from multiple 
follow-up timepoints up to 2 years after enrolment, enabling 
not only longitudinal analysis but analysis using the trajec-
tory of change of physical performance over time. We were 
also able to measure both frailty (using a variant of a well-
established frailty score) and physical performance in sev-
eral complementary ways including measures of lower limb 
function (the SPPB), upper limb function (grip strength) 
and endurance/cardiorespiratory function (the six-minute 
walk distance). Finally, our focus on older people with CKD 
stages 4 and 5 is likely to maximise our ability to examine 
the impact of metabolic derangements associated with CKD. 
Such derangements (e.g. anaemia, derangements of bone and 
mineral metabolism, uraemic toxin retention) are thought 
to be less prominent in moderate CKD (GFR 30–59 mL/
min/1.73  m2), and thus less of an effect on physical perfor-
mance would be available to detect.
Some limitations also deserve comment. In line with 
the characteristics of the study population (advanced age, 
multimorbidity and frailty), dropout due to dialysis, ill-
ness or death was common during follow-up, increasing the 
amount of missing data and hence reducing our ability to 
detect modest associations. Despite the pragmatic design of 
the BiCARB trial, the analysis population was still drawn 
from a randomised controlled trial and are therefore likely 
to be fitter than the general population of older people with 
advanced CKD. In addition, the relatively low proportion of 
women, low ethnic diversity and UK origin of data, are all 
likely to limit the generalisability of the findings. It is also 
important to note that no adjustment was made for multi-
ple testing; given the number of comparisons made in the 
analysis, it is possible that those associations that did reach 
significance could still be due to chance, and the findings 
require replication in other cohorts.
Although previous research has clearly demonstrated 
an association between CKD and both frailty and impaired 
physical performance, it has not been clear what aspects of 
CKD pathophysiology are most important in driving this 
association—nor indeed how much of the association is 
causal. Based on our results, interventions to improve physi-
cal performance and frailty in older people by targeting 
aspects of pathophysiology found in CKD may be of limited 
benefit. Of the domains tested, improving cardiovascular 
health, vitamin D supplementation and possibly weight loss 
for people with obesity may be worthy of further study as 
interventions to improve physical performance in randomised 
controlled trials for patients with CKD. The effects of vitamin 
D supplementation on physical performance in older people 
without CKD have been well studied; current analyses do not 
support a clinically important effect of supplementation on 
physical performance [29]. Similarly, bicarbonate therapy for 
metabolic acidosis does not appear to be effective at improv-
ing physical performance in older people, at least not at doses 
used currently in clinical practice [16]. Studies examining the 
relationship between physical performance and other modifi-
able factors (e.g. specific uraemic toxins) would, however, be 
informative; it is also possible that CKD pathophysiological 
derangements may be of more importance in driving frailty 
in younger people with CKD, who will tend to have less of 
the comorbidities that are also likely to limit physical per-
formance independent of CKD. The greatest benefit may, 
however, come from interventions that target a broad range 
of diseases, either by pleiotropic effects (effects on a broad 
range of molecular targets) or by targeting specific funda-
mental biological pathways that underpin multiple diseases. 
Exercise training remains the archetype of such interven-
tions, and remains the only intervention with solid evidence 
to ameliorate frailty and improve physical performance in 
older people [30], although other pathways such as inflam-
mation and oxidative stress common to multiple diseases may 
also provide fruitful lines for future research.
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